Scalper1 News
Specialty drugmaker and IBD 50 stock Salix Pharmaceuticals (SLXP) said Tuesday that its drug Xifaxan succeeded in a late-stage study of irritable bowel syndrome with diarrhea, sending Salix stock up more than 11% to a new high in morning trading on the stock market today. The Salix press release provided few numbers but said that patients in the phase-three study who took Xifaxan, known generally as rifaximin, for 14 days showed statistically Scalper1 News
Scalper1 News